Headlines about AnaptysBio (NASDAQ:ANAB) have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AnaptysBio earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.8571674943688 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

ANAB has been the topic of several recent analyst reports. JMP Securities lifted their price objective on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Credit Suisse Group lifted their price objective on AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, August 25th. Zacks Investment Research cut AnaptysBio from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Jefferies Group initiated coverage on AnaptysBio in a report on Thursday, November 9th. They set a “buy” rating and a $101.00 price objective on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $75.00 price objective (up previously from $37.00) on shares of AnaptysBio in a report on Friday, October 13th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $84.78.

Shares of AnaptysBio (NASDAQ ANAB) opened at $84.72 on Wednesday. AnaptysBio has a 1 year low of $15.17 and a 1 year high of $88.17. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.02. research analysts anticipate that AnaptysBio will post -1.72 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/06/anaptysbio-anab-receives-daily-news-sentiment-score-of-0-07.html.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Insider Buying and Selling by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Stock Ratings for AnaptysBio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc and related stocks with our FREE daily email newsletter.